ABVC BioPharma, Inc. (ABVC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ABVC BioPharma, Inc. (ABVC) trades at $1.89 with AI Score 28/100 (Grade F). ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs and medical devices to address unmet medical needs. Market cap: $27.35M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for ABVC: ABVC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ABVC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ABVC: 3/7 perspectives are bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →ABVC BioPharma, Inc. (ABVC) Healthcare & Pipeline Overview
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company developing drugs and medical devices, focusing on oncology and central nervous system disorders. Their pipeline includes candidates in Phase I/II and Phase II trials, targeting unmet needs in triple-negative breast cancer, major depressive disorder, and ADHD, positioning them in a competitive biotech landscape.
What Is the Investment Thesis for ABVC?
ABVC BioPharma presents a high-risk, high-reward investment profile typical of clinical-stage biopharmaceutical companies. The company's value hinges on the successful progression of its drug candidates through clinical trials, particularly ABV-1501 for triple-negative breast cancer and ABV-1504 for major depressive disorders. Positive Phase II results for ABV-1505 in ADHD could also drive significant value. However, the company faces substantial risks, including clinical trial failures, regulatory hurdles, and the need for additional capital. With a market cap of $27.35M and a beta of 0.27, ABVC exhibits characteristics of a volatile micro-cap stock. Investors should closely monitor clinical trial outcomes and regulatory milestones as key value drivers. The lack of dividend yield reflects the company's focus on reinvesting earnings into R&D.
Based on FMP financials and quantitative analysis
ABVC Key Highlights
- ABV-1501 is in Phase I/II clinical trials as a combination therapy for triple negative breast cancer, addressing a critical unmet need in oncology.
- ABV-1504 has completed Phase II clinical trials for major depressive disorders, indicating potential efficacy in a large patient population.
- ABV-1505 is in Phase II clinical trials for attention deficit hyperactivity disorder, targeting a significant market in pediatric and adult populations.
- ABVC BioPharma has a co-development agreement with Rgene Corporation, enhancing its R&D capabilities and pipeline development.
- The company operates with 16 employees, reflecting a lean operational structure typical of clinical-stage biopharmaceutical firms.
Who Are ABVC's Competitors?
ABVC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| ZLDPF Zealand Pharma A/S | $45.61 | -2.85% | $3.23B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ABVC's Key Strengths?
- Diverse pipeline of drug candidates in various stages of clinical trials.
- Focus on unmet medical needs in oncology and CNS disorders.
- Strategic collaborations with research institutions and other companies.
- Subsidiary of YuanGene Corporation, providing access to resources and expertise.
What Are ABVC's Weaknesses?
- Clinical-stage company with no currently marketed products.
- High dependence on successful clinical trial outcomes.
- Limited financial resources and potential need for additional funding.
- Small team size with 16 employees.
What Could Drive ABVC Stock Higher?
- Phase II trial results for ABV-1505 in ADHD expected in Q3 2026.
- Enrollment and data readout from the Phase I/II clinical trial of ABV-1501 for triple-negative breast cancer.
- Continued progress in strategic collaborations with Rgene Corporation, BioHopeKing Corporation, and BioFirst Corporation.
- Potential FDA feedback on ABV-1504 development pathway by Q4 2026.
What Are the Key Risks for ABVC?
- Financial-distress signal — its Altman Z-Score of -5.24 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-92.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays in the development of ABV-1501, ABV-1504, and ABV-1505.
- Regulatory hurdles and potential rejection of drug candidates by the FDA.
- Competition from larger pharmaceutical companies with greater resources.
- Dependence on securing additional funding to support clinical development programs.
- Patent expirations and generic competition for key drug candidates.
What Are the Growth Opportunities for ABVC?
- Expansion in Oncology: ABVC's ABV-1501 targets triple-negative breast cancer, a particularly aggressive form of the disease with limited treatment options. Success in Phase II/III trials could lead to significant market penetration, addressing a market estimated at billions of dollars. The company's focus on combination therapy offers a potential competitive advantage. Timeline: Potential market entry within 3-5 years pending successful trial outcomes and regulatory approvals.
- CNS Disorder Therapeutics: ABV-1504 for major depressive disorders and ABV-1505 for ADHD represent significant growth opportunities in the central nervous system (CNS) therapeutic area. The market for antidepressants and ADHD medications is substantial, with increasing prevalence rates. Positive clinical trial results could position ABVC to capture a share of this market. Timeline: Potential market entry within 3-5 years pending successful trial outcomes and regulatory approvals.
- Strategic Partnerships and Collaborations: ABVC's existing collaborations with Rgene Corporation, BioHopeKing Corporation, and BioFirst Corporation provide a foundation for further strategic partnerships. Expanding these collaborations could accelerate drug development, broaden the company's pipeline, and provide access to new technologies and markets. Timeline: Ongoing, with potential for new partnerships to be established within the next 1-2 years.
- Advancement of Early-Stage Pipeline: ABVC's early-stage programs, including ABV-1703 for pancreatic cancer and ABV-1702 for myelodysplastic syndromes, represent longer-term growth opportunities. Successful completion of Phase I trials and progression to Phase II could significantly increase the company's valuation. Timeline: Potential for significant value creation within 5-7 years as these programs advance through clinical development.
- Vitargus for Retinal Detachment: ABV-1701 Vitargus, targeting retinal detachment or vitreous hemorrhage, represents a niche market opportunity within ophthalmology. Successful development and commercialization of Vitargus could provide a steady revenue stream and diversify ABVC's product portfolio. The market for retinal detachment treatments is growing due to the aging population and increasing prevalence of diabetes. Timeline: Potential market entry within 3-5 years pending successful trial outcomes and regulatory approvals.
What Opportunities Does ABVC Have?
- Positive clinical trial results leading to regulatory approvals.
- Expansion of strategic partnerships and collaborations.
- Out-licensing or sale of drug candidates to larger pharmaceutical companies.
- Advancement of early-stage pipeline programs.
What Threats Does ABVC Face?
- Clinical trial failures or delays.
- Regulatory hurdles and rejection of drug candidates.
- Competition from other biopharmaceutical companies.
- Patent expirations and generic competition.
What Are ABVC's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Clinical trial data demonstrating efficacy and safety.
- Strategic collaborations with research institutions and pharmaceutical companies.
- Focus on unmet medical needs in specific therapeutic areas.
What Does ABVC Do?
ABVC BioPharma, Inc., founded with the mission to address unmet medical needs, is a clinical-stage biopharmaceutical company dedicated to the development of innovative drugs and medical devices. The company's pipeline encompasses a range of therapeutic candidates targeting critical conditions such as cancer, central nervous system disorders, and ophthalmological diseases. ABVC's lead product candidates include ABV-1501, a combination therapy in Phase I/II clinical trials for triple-negative breast cancer, and ABV-1504, which has completed Phase II clinical trials for major depressive disorders. Additionally, ABV-1505 is in Phase II clinical trials for attention deficit hyperactivity disorder (ADHD). Other notable programs include ABV-1703 for pancreatic cancer, ABV-1702 for myelodysplastic syndromes, ABV-1601 for depression in cancer patients, and ABV-1701 Vitargus for retinal detachment or vitreous hemorrhage. ABVC BioPharma operates primarily in the United States, with its headquarters in Fremont, California. The company fosters strategic collaborations to enhance its research and development efforts, including a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. As a subsidiary of YuanGene Corporation, ABVC leverages its parent company's resources and expertise to advance its clinical programs. ABVC BioPharma is committed to bringing innovative solutions to patients with limited treatment options, focusing on rigorous clinical development and strategic partnerships to maximize its impact on healthcare.
What Products and Services Does ABVC Offer?
- Develops drugs and medical devices to address unmet medical needs.
- Focuses on clinical-stage biopharmaceutical development.
- Conducts clinical trials for various drug candidates.
- Targets conditions like cancer, depression, and ADHD.
- Collaborates with other companies for research and development.
- Seeks regulatory approvals for its products in the United States.
- Specializes in combination therapies and novel treatments.
How Does ABVC Make Money?
- Develops and patents novel drug candidates.
- Conducts clinical trials to demonstrate safety and efficacy.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments, royalties, and potential direct sales.
What Industry Does ABVC Operate In?
ABVC BioPharma operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and high capital demands. The industry is driven by the increasing need for innovative therapies to address unmet medical needs, particularly in areas like oncology and central nervous system disorders. ABVC's focus on clinical-stage development places it among numerous companies vying to bring novel drugs to market. Success in this landscape requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships to navigate the complex regulatory and commercialization pathways. The biotechnology industry is experiencing growth, driven by technological advancements and increasing healthcare expenditures.
Who Are ABVC's Key Customers?
- Patients suffering from triple-negative breast cancer.
- Patients with major depressive disorders.
- Individuals diagnosed with attention deficit hyperactivity disorder (ADHD).
- Patients with pancreatic cancer or myelodysplastic syndromes.
- Individuals with retinal detachment or vitreous hemorrhage.
Company Profile
ABVC BioPharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Fremont, US. The company is led by CEO Uttam Yashwant Patil. ABVC has traded publicly since 2004.
F-Score 1/9Financial Health
ABVC BioPharma, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.24 places it in the distress zone, a signal of elevated financial risk.
ROE -92%Key Financial Metrics
Return on equity for ABVC BioPharma, Inc. stands at -92.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -47.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -16.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.12 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -26.3%, the inverse of the P/E and a quick read on earnings relative to price.
ABVC Valuation & Market Position
With a $27.35M market cap, ABVC BioPharma, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ABVC's quantitative score of 28/100 is below the peer average of 76/100.
FY2026 estForward Outlook
Wall Street analysts project ABVC BioPharma, Inc. revenue of about $35.3M for fiscal 2026, with EPS near $1.30.
ABVC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insider buying suggests confidence in ABVC's pipeline. It's like the executives are doubling down, signaling they believe in the company's future prospects, similar to how insiders loaded up on Tesla before its big 2020 run.
- Community buzz is picking up around ABVC's cancer drug development. It feels like the market is starting to recognize the potential, a bit like the early days of mRNA vaccine excitement.
- ABVC's strategic partnerships are gaining traction, expanding their reach. This kind of expansion reminds me of how companies like Amazon built their empire through smart collaborations.
- The overall market sentiment towards biotech is improving, lifting ABVC along with it. A rising tide lifts all boats, as they say, and ABVC seems to be benefiting from this renewed interest in the sector.
Bear Case
- Recent insider sales, even if small, can create a perception of uncertainty. It's like a few cracks in the foundation, making some investors nervous, similar to seeing executives bail before a company's earnings report.
- Community sentiment is divided, with some questioning the timeline for ABVC's drug approvals. The uncertainty is a bit like waiting for a delayed flight – you're not sure when it'll actually take off.
- Competition in the biopharma space is fierce, and ABVC faces established players. Think of it as a small startup trying to compete with giants like Pfizer – it's an uphill battle.
- Market perception of smaller biotech companies can be volatile, making ABVC susceptible to sudden drops. It's like being on a rollercoaster – exciting, but with the potential for a sudden plunge.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
ABVC Latest News
-
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga · Jun 22, 2026
-
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga · Jun 4, 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
ABVC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ABVC.
Price Targets
Wall Street price target analysis for ABVC.
ABVC MoonshotScore
What does this score mean?
The MoonshotScore rates ABVC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Uttam Yashwant Patil
CEO
Uttam Yashwant Patil serves as the CEO of ABVC BioPharma, Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries. Patil's expertise spans drug development, clinical trials, and regulatory affairs. He has held leadership positions in various companies, contributing to the advancement of novel therapies. Patil's educational background includes advanced degrees in science and business, providing a strong foundation for his role at ABVC BioPharma.
Track Record: Under Uttam Yashwant Patil's leadership, ABVC BioPharma has focused on advancing its pipeline of drug candidates through clinical trials. Key milestones include the completion of Phase II clinical trials for ABV-1504 in major depressive disorders and the ongoing Phase I/II trials for ABV-1501 in triple-negative breast cancer. Patil has also overseen strategic collaborations aimed at enhancing the company's research and development capabilities.
Common Questions About ABVC (Healthcare)
What does ABVC BioPharma, Inc. do?
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing drugs and medical devices that address unmet medical needs. The company focuses on advancing its pipeline of drug candidates through clinical trials, targeting conditions such as triple-negative breast cancer, major depressive disorders, and ADHD. ABVC operates primarily in the United States and collaborates with other companies to enhance its research and development efforts. Their business model revolves around developing and patenting novel drug candidates, conducting clinical trials, and seeking regulatory approvals for commercialization.
What do analysts say about ABVC stock?
Given ABVC BioPharma's market capitalization of $27.35M, analyst coverage may be limited. However, the company's value is closely tied to the progress of its clinical trials, particularly for ABV-1501, ABV-1504, and ABV-1505. Investors should monitor clinical trial results and regulatory milestones as key indicators of the company's potential. The company's beta of 0.27 suggests lower volatility compared to the overall market, but micro-cap stocks are inherently risky. The lack of a dividend reflects the company's focus on reinvesting earnings into R&D.
What are the main risks for ABVC?
ABVC BioPharma faces several risks inherent to clinical-stage biopharmaceutical companies. These include the potential for clinical trial failures or delays, regulatory hurdles and potential rejection of drug candidates by the FDA, competition from larger pharmaceutical companies with greater resources, and dependence on securing additional funding to support clinical development programs. Additionally, patent expirations and generic competition pose a threat to the company's long-term revenue potential. Investors should carefully consider these risks before investing in ABVC.
What are the key factors to evaluate for ABVC?
ABVC BioPharma, Inc. (ABVC) holds an AI score of 28/100 (low). Not financial advice.
How frequently does ABVC data refresh on this page?
ABVC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ABVC's recent stock price performance?
ABVC BioPharma, Inc. (ABVC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse pipeline of drug candidates in various stages of clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ABVC overvalued or undervalued right now?
Valuing ABVC BioPharma, Inc. (ABVC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ABVC?
Before investing in ABVC BioPharma, Inc. (ABVC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is limited by the availability of detailed financial data for ABVC BioPharma, Inc.